NCT06842472View on ClinicalTrials.gov

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Breast Cancer
Interventions
DRUG

Ursodeoxycholic Acid (URSO)

UDCA 250 mg twice daily, starting 7 days before radiotherapy and continuing for 1 month after completion.

RADIATION

Radiotherapy

Radiotherapy (SBRT) with a dose of 24Gy/3 fractions within 3 weeks after the first immunotherapy dose.

DRUG

Adebrelimab (PD-L1 inhibitor)

Adebrelimab (PD-L1 inhibitor) 1200 mg on Day 1, every 3 weeks.

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER